• Yujie Kong, Chen Cai, Li Ling, Li Zeng, Meihong Wu, Yanyun Wu, Wei Zhang, and Zhong Liu.
• Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, 610052, Chengdu, Sichuan Province, PR China; Key laboratory of transfusion adverse reactions, CAMS, 610052, Chengdu, Sichuan Province, PR China.
• Transfus Apher Sci. 2020 Oct 1; 59 (5): 102820.

BackgroundBecause treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored.Case Presentation And TreatmentA male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion.ResultsAfter convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 × 104 to 1.39 × 103 copies/mL) and became undetectable after the second transfusion.ConclusionsWith the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly.Copyright © 2020. Published by Elsevier Ltd.

16 keywords...

hide…